These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29510588)

  • 1. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
    Nakano K; Takahashi S
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
    Sethi TK; Keedy VL
    Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies.
    Penel N; Lebellec L; Blay JY; Robin YM
    Crit Rev Oncol Hematol; 2020 Jun; 150():102960. PubMed ID: 32320927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
    Ryan CW; Desai J
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.
    Harwood JL; Alexander JH; Mayerson JL; Scharschmidt TJ
    Orthop Clin North Am; 2015 Oct; 46(4):587-608. PubMed ID: 26410647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in bone and soft tissue sarcoma in children and adolescents.
    Thompson PA; Chintagumpala M
    Curr Oncol Rep; 2012 Apr; 14(2):197-205. PubMed ID: 22302601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pathways and molecular targets for the treatment of sarcoma.
    Frith AE; Hirbe AC; Van Tine BA
    Curr Oncol Rep; 2013 Aug; 15(4):378-85. PubMed ID: 23661264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
    Vincenzi B; Badalamenti G; Napolitano A; Spalato Ceruso M; Pantano F; Grignani G; Russo A; Santini D; Aglietta M; Tonini G
    Crit Rev Oncol Hematol; 2017 Oct; 118():1-6. PubMed ID: 28917265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ; Gandhi A
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Soft tissue sarcomas and gastrointestinal stromal tumors].
    Reichardt P
    Internist (Berl); 2016 Mar; 57(3):245-56. PubMed ID: 26907871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib for the Treatment of Sarcoma.
    Blay JY; Duffaud F; George S; Maki RG; Penel N
    Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G; Lee ATJ; Huang PH; Jones RL
    Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
    Tanaka K; Ozaki T
    Jpn J Clin Oncol; 2022 May; 52(6):526-530. PubMed ID: 35292817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
    Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A; Jones RL
    Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in soft tissue sarcomas.
    Judson I
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii277-80. PubMed ID: 20943628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
    Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
    JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting sarcomas: novel biological agents and future perspectives.
    Mahalingam D; Mita A; Sankhala K; Swords R; Kelly K; Giles F; Mita MM
    Curr Drug Targets; 2009 Oct; 10(10):937-49. PubMed ID: 19860642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.